Future Financial Wealth Managment LLC Makes New $158,000 Investment in Humana Inc. (NYSE:HUM)

Future Financial Wealth Managment LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 500 shares of the insurance provider’s stock, valued at approximately $158,000.

Other large investors have also modified their holdings of the company. Mendota Financial Group LLC lifted its holdings in Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares during the period. Aurora Investment Counsel increased its stake in shares of Humana by 1.3% during the 4th quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock worth $1,155,000 after purchasing an additional 29 shares during the last quarter. Capital Advisors Ltd. LLC grew its stake in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after buying an additional 31 shares during the last quarter. EP Wealth Advisors LLC grew its stake in Humana by 1.6% in the 4th quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after buying an additional 37 shares during the last quarter. Finally, CarsonAllaria Wealth Management Ltd. grew its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

HUM stock opened at $243.20 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $530.54. The firm has a market cap of $29.31 billion, a P/E ratio of 15.14, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The stock has a 50-day simple moving average of $331.35 and a 200-day simple moving average of $341.88.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $8.94 EPS. On average, equities analysts predict that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 1.46%. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HUM. Stephens cut shares of Humana from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Bank of America lowered shares of Humana from a “neutral” rating to an “underperform” rating and dropped their price objective for the company from $376.00 to $247.00 in a research note on Wednesday, October 2nd. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the company from $519.00 to $253.00 in a research note on Monday. Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, TD Cowen downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their target price for the stock from $402.00 to $261.00 in a research note on Monday. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $324.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.